Terms: = Lymphoma AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
5 results:
1. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
Schick M; Habringer S; Nilsson JA; Keller U
Br J Haematol; 2017 Dec; 179(5):724-738. PubMed ID: 29171017
[TBL] [Abstract] [Full Text] [Related]
2. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract] [Full Text] [Related]
3. Genetics of pleiotropic effects of dexamethasone.
Ramsey LB; Pounds S; Cheng C; Cao X; Yang W; Smith C; Karol SE; Liu C; Panetta JC; Inaba H; Rubnitz JE; Metzger ML; Ribeiro RC; Sandlund JT; Jeha S; Pui CH; Evans WE; Relling MV
Pharmacogenet Genomics; 2017 Aug; 27(8):294-302. PubMed ID: 28628558
[TBL] [Abstract] [Full Text] [Related]
4. Small-cell lung cancers in patients who never smoked cigarettes.
Varghese AM; Zakowski MF; Yu HA; Won HH; Riely GJ; Krug LM; Kris MG; Rekhtman N; Ladanyi M; Wang L; Berger MF; Pietanza MC
J Thorac Oncol; 2014 Jun; 9(6):892-6. PubMed ID: 24828667
[TBL] [Abstract] [Full Text] [Related]
5. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract] [Full Text] [Related]
